Ventyx biosciences to participate in the h.c. wainwright autoimmune & inflammatory disease virtual conference

Encinitas, calif., march 24, 2023 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that company executives will participate in a fireside chat at the h.c. wainwright autoimmune & inflammatory disease virtual conference being held on march 30, 2023.
VTYX Ratings Summary
VTYX Quant Ranking